Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Pricing of new drugs: deadlock  Editorial  Is it possible for countries to provide access to new, very expensive drugs while balancing the books of their health insurance system? The pharmaceutical industry's pursuit of maximum profits is making it increasingly difficult to reconcile these competing pressures. Full article available for download (FREE) 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Relugolix + estradiol + norethisterone acetate (Ryeqo°) in endometriosis  Marketing Authorisations  Endometriosis is a condition related to the presence of uterine mucosal tissue (endometrium) outside of the uterus. When paracetamol or a nonsteroidal anti-inflammatory drug are not sufficient to relieve endometriosis-related pain, a hormonal contraceptive or an intrauterine device (IUD) that delivers levonorgestrel are options. Relugolix, a GnRH antagonist that induces menopausal symptoms, combined with an oestrogen-progestogen combination intended to attenuate these symptoms, is already authorised for the treatment of uterine fibroid symptoms, a situation in which it has an unfavourable harm-benefit balance. It is now also authorised for the treatment of endometriosis symptoms.  Full article available for download by subscribers 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Live attenuated cholera O1 vaccine (Vaxchora°)  Marketing Authorisations  The mainstay of cholera prevention and control is to improve access to clean drinking water, sewage systems and personal hygiene. A live attenuated cholera O1 vaccine has been authorised in the European Union under the brand name Vaxchora°. For people living in countries where cholera is endemic or causes epidemics or travellers visiting such countries, is this vaccine more effective than the other available cholera vaccines? And what are its adverse effects? Full article available for download by subscribers 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ PD-1 or PD-L1 immune checkpoint inhibitors: cholangitis  Adverse Effects  In 2024, a French team published an analysis of 48 reports of cholangitis attributed to a PD-1 or PD-L1 immune checkpoint inhibitor, recorded in the national pharmacovigilance database. 4 patients died, 2 from liver injury.  Full article available for download by subscribers 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Long-term PPI treatment: increased incidence of gastric cancer and gastric cancer recurrence  Adverse Effects  In 2023, in two cohort studies including about 300 000 patients who had received at least one treatment for Helicobacter pylori infection, the risk of gastric cancer was about 4-fold greater in patients with the most exposure to PPIs than in those who had little or no exposure.  Full article available for download by subscribers 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Antineoplastic drugs that do not represent a therapeutic advance: still highly profitable  Outlook  Antineoplastic drugs that provide little or no progress for patients are nonetheless significant sources of revenue for pharmaceutical companies: between 1995 and 2020, these drugs generated half as much revenue as those that represented a major therapeutic advance. Full article available for download (FREE) 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Anti-competitive practices: a very "inventive" pharmaceutical industry  Outlook  A total of €780 million in fines was imposed in the European Union over the period 2018-2022. More than half of this sum related to a case in France that has been appealed by the companies concerned. Full article available for download (FREE) 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Insulin icodec in type 1 or type 2 diabetes • Mysimba° (bupropion + naltrexone): European marketing authorisation maintained • Caftors: liver function abnormalities in breastfed infants • Depakine: mother who sounded the alarm receives compensation > Subscribe now 1 September 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2025 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---